BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• 

  Drug shortages

  FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period

  After a couple months of uncertainty, the FDA has told compounding pharmacies that they have 60 to 90 days before the agency will enforce rules to stop their production of GLP-1s.

  December 19, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Layoffs

  The 5 Largest Biopharma Layoffs of 2024

  While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees in 2024.

  December 19, 2024

   · 

  7 min read

   · 

  Angela Gabriel
• 

  Business

  Analysis vs Beliefs, CEO Challenges, GLP-1 Investments

  In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh speculate on the impending Trump administration, discuss current challenges faced by CEOs and weigh investment in GLP-1s.

  December 19, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Cell therapy

  Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD

  The approval concludes what has been a difficult regulatory path for Ryoncil, which suffered FDA rejections in 2020 and 2023.

  December 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs

  The closures follow Novartis’s acquisition of MorphoSys earlier this year.

  December 19, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  GLP-1

  GLP-1s Potentially ‘Transformative’ but Could Lead to ‘Distorted’ Obesity Care: WHO

  According to the World Health Organization, GLP-1 receptor agonists are currently being used in a highly medicalized manner. Healthcare systems need to enact more holistic solutions, focusing on health promotion, disease prevention and policy interventions.

  December 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pain

  Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy

  Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their concerns as the company’s share price fell 13% in premarket trading.

  December 19, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Parkinson’s disease

  Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial

  The report comes just two days after Novartis announced its own Parkinson’s drug failure.

  December 19, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Alzheimer’s disease

  BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal

  BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies.

  December 19, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• Press Releases

  Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

  December 19, 2024

   · 

  11 min read